A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Select Advanced Solid Tumors Clinical Trial

Official title:
A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.

Clinical Trial Description

This is a Phase 1 multicenter, open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02705482
Study type	Interventional
Source	MedImmune LLC
Contact
Status	Completed
Phase	Phase 1
Start date	March 30, 2016
Completion date	August 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06402201` - First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors	Phase 1
Terminated	`NCT03973333` - Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab	Phase 1/Phase 2
Terminated	`NCT03515551` - Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers	Phase 1/Phase 2
Recruiting	`NCT04262466` - Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors	Phase 1/Phase 2